Cargando…
The efficacy and safety of paclitaxel plus bevacizumab therapy in breast cancer patients with visceral crisis
BACKGROUND: Visceral crisis in metastatic breast cancer (MBC) is defined as severe organ dysfunction requiring rapidly efficacious therapy. Although weekly paclitaxel plus bevacizumab (wPTX + BV) achieves a high response rate in human epidermal growth factor receptor 2 (HER2)-negative MBC, the effic...
Autores principales: | Funasaka, Chikako, Naito, Yoichi, Kusuhara, Shota, Nakao, Takehiro, Fukasawa, Yoko, Mamishin, Kanako, Komuro, Ayumi, Okunaka, Mashiro, Kondoh, Chihiro, Harano, Kenichi, Kogawa, Takahiro, Matsubara, Nobuaki, Hosono, Ako, Kawasaki, Toshikatsu, Mukohara, Toru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8095047/ https://www.ncbi.nlm.nih.gov/pubmed/33901922 http://dx.doi.org/10.1016/j.breast.2021.04.001 |
Ejemplares similares
-
The impact of the COVID‐19 pandemic on perioperative chemotherapy for breast cancer
por: Baba, Kaede, et al.
Publicado: (2023) -
Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer
por: Nakajima, Hiromichi, et al.
Publicado: (2022) -
Intestinal Perforation due to Neutropenic Enterocolitis in a Patient Treated with Bevacizumab for Ovarian Cancer
por: Sasaki, Akinori, et al.
Publicado: (2020) -
Use of eribulin as an earlier-line chemotherapy for patients with HER2-negative metastatic breast cancer
por: Shingaki, Sumito, et al.
Publicado: (2020) -
Cisplatin and S‐1 for urachal carcinoma: A single‐institution case series
por: Urasaki, Tetsuya, et al.
Publicado: (2019)